New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesilute vs Gonadorelin

Vesilute vs Gonadorelin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
Sexual Health & LibidoAnti-Aging & Longevity
Gonadorelin
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
100 mcg
Frequency
Daily for 10–30 days
Twice daily (every 12 hours)
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Maintains testicular size during TRT
  • Preserves fertility and sperm production during testosterone use
  • Stimulates endogenous LH/FSH production
  • Maintains HPG axis function during exogenous hormone use
  • Used for HCG-free TRT protocols
  • Helps restart natural testosterone production (PCT)
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Injection site reactions
  • Headache
  • Nausea at initiation
  • Tachycardia (rare)
  • +1 more
Stacks With